• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    37550302.pdf
    Size:
    348.8Kb
    Format:
    PDF
    Description:
    Identified with Open Access button
    Download
    Authors
    Coombes, R. C.
    Howell, Sacha J
    Lord, S. R.
    Kenny, L.
    Mansi, J.
    Mitri, Z.
    Palmieri, C.
    Chap, L. I.
    Richards, P.
    Gradishar, W.
    Sardesai, S.
    Melear, J.
    O'Shaughnessy, J.
    Ward, P.
    Chalasani, P.
    Arkenau, T.
    Baird, R. D.
    Jeselsohn, R.
    Ali, S.
    Clack, G.
    Bahl, A.
    McIntosh, S.
    Krebs, Matthew G
    Show allShow less
    Affiliation
    Imperial College, South Kensington, London, UK
    Issue Date
    2023
    
    Metadata
    Show full item record
    Abstract
    None
    Citation
    Coombes RC, Howell S, Lord SR, Kenny L, Mansi J, Mitri Z, et al. Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib. Nature communications. 2023 Aug 7;14(1):4741. PubMed PMID: 37550302. Pubmed Central PMCID: PMC10406871. Epub 2023/08/08. eng.
    Journal
    Nature Communications
    URI
    http://hdl.handle.net/10541/626497
    DOI
    10.1038/s41467-023-40561-x
    PubMed ID
    37550302
    Additional Links
    https://dx.doi.org/10.1038/s41467-023-40561-x
    Type
    Other
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1038/s41467-023-40561-x
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
    • Authors: Coombes RC, Howell S, Lord SR, Kenny L, Mansi J, Mitri Z, Palmieri C, Chap LI, Richards P, Gradishar W, Sardesai S, Melear J, O'Shaughnessy J, Ward P, Chalasani P, Arkenau T, Baird RD, Jeselsohn R, Ali S, Clack G, Bahl A, McIntosh S, Krebs MG
    • Issue date: 2023 Jul 24
    • Correction: The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.
    • Authors: Constantin TA, Varela-Carver A, Greenland KK, de Almeida GS, Olden E, Penfold L, Ang S, Ormrod A, Leach DA, Lai CF, Ainscow EK, Bahl AK, Carling D, Fuchter MJ, Ali S, Bevan CL
    • Issue date: 2024 Mar
    • Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
    • Authors: El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I
    • Issue date: 2017 Jun 24
    • Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
    • Authors: Schuler M, Cho BC, Sayehli CM, Navarro A, Soo RA, Richly H, Cassier PA, Tai D, Penel N, Nogova L, Park SH, Schostak M, Gajate P, Cathomas R, Rajagopalan P, Grevel J, Bender S, Boix O, Nogai H, Ocker M, Ellinghaus P, Joerger M
    • Issue date: 2019 Oct
    • Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
    • Authors: Tamura K, Tsurutani J, Takahashi S, Iwata H, Krop IE, Redfern C, Sagara Y, Doi T, Park H, Murthy RK, Redman RA, Jikoh T, Lee C, Sugihara M, Shahidi J, Yver A, Modi S
    • Issue date: 2019 Jun
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.